Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Type: Poster Session

Time: Saturday June 3, 8:00 AM to 11:30 AM

Location: Hall A

Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment.

Sub-category:
Adjuvant Therapy

Category:
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Meeting:
2017 ASCO Annual Meeting

Abstract No:
8527

Poster Board Number:
Poster Session (Board #263)

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 8527)

Author(s): S.P. Somashekhar, Martín-J. Sepúlveda, Andrew D Norden, Amit Rauthan, Kumar Arun, Poonam Patil, Ramya Y Ethadka, Rohit C Kumar; Manipal Comprehensive Cancer Center, Bangalore, India; IBM, Saint Augustine, FL; IBM Watson Health, Cambridge, MA; Manipal Hospital, Bangalore, India

Abstract Disclosures

Abstract:

Background: IBM Watson for Oncology is an artificial intelligence cognitive computing system that provides confidence-ranked, evidence-based treatment recommendations for cancer. In the present study, we examine the level of agreement for lung and colorectal cancer therapy between the multidisciplinary tumour board from Manipal Comprehensive Cancer Centre in Bangalore, India, and Watson for Oncology. Methods: Watson for Oncology is a Memorial Sloan Kettering Cancer Center (New York, USA) trained cognitive computing system that uses natural language processing and machine learning to provide treatment recommendations. It processes structured and unstructured data from medical literature, treatment guidelines, medical records, imaging, lab and pathology reports, and the expertise of Memorial Sloan Kettering experts to formulate therapeutic recommendations. Treatment recommendations are provided in three categories: recommended, for consideration and not recommended. In this report we provide the results of the independent and blinded evaluation by the multidisciplinary tumour board and Watson for Oncology of 362 total cancer cases comprised of 112 lung, 126 colon and 124 rectal cancers seen at the Centre within the last three years. The recommendations of the two agents were compared for agreement and considered concordant when the tumour board recommendation was included in the recommended or for consideration categories of the treatment advisor. Results: Overall, treatment recommendations were concordant in 96.4% of lung, 81.0% of colon and 92.7% of rectal cancer cases. By tumour stage, treatment recommendations were concordant in 88.9% of localized and 97.9% of metastatic lung cancer, 85.5% of localized and 76.6% of metastatic colon cancer, and 96.8% of localized and 80.6% of metastatic rectal cancer. Conclusions: Treatment recommendations made by the Manipal multidisciplinary tumour board and Watson for Oncology were highly concordant in the cancers examined. This cognitive computing technology holds much promise in helping oncologists make information intensive, evidence based treatment decisions.

 
Other Abstracts in this Sub-Category:

 

1. Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).

Meeting: 2017 ASCO Annual Meeting Abstract No: 8500 First Author: Yi-Long Wu
Category: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Adjuvant Therapy

 

2. Survival benefit of systemic chemotherapy given as adjuvant (ACT) after thoracic surgery for N0-1 non-small cell lung cancer (NSCLC) patients (pts) with synchronous brain metastasis (SBM).

Meeting: 2017 ASCO Annual Meeting Abstract No: 8525 First Author: Sarah Shin
Category: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Adjuvant Therapy

 

3. The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: A decision, effectiveness, and cost-effectiveness analysis.

Meeting: 2017 ASCO Annual Meeting Abstract No: 8526 First Author: Jessica Lynn Hudson
Category: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Adjuvant Therapy

 

More...